OnCo
trialsTrial

Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia

A phase 2 trial of Fostamatinib and Ruxolitinib in Primary myelofibrosis, run by Washington University School of Medicine, recorded as terminated on the registry.